Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Artios Pharma Ltd
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04657068CT.gov A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT01835041CT.gov CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Acinar Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Artios Pharma Ltd | P2 | BB · 71 |
| Fluorouracilum | Yale University | P2 | BBB |
| Oxaliplatin | Yale University | P2 | BB |
| Metformin | Case Comprehensive Cancer Center | P2 | BB |
| Wild-Type Reovirus | National Cancer Institute (NCI) | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Alliance for Clinical Trials in Oncology | P2/3 | B |
| Carboplatin | National Cancer Institute (NCI) | P2 | B |
| Bryostatin 1 | National Cancer Institute (NCI) | P2 | B |
| Triapine | National Cancer Institute (NCI) | P2 | B |
+26 more in the Pancreatic Acinar Cell Carcinoma cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Pancreatic Acinar Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-pancreatic-acinar-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →